Stocktoria
Korro Bio, Inc. KRRO
Korro Bio, Inc. (KRRO) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $6.4M at a -1834.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.621 |
| Retained earnings / assets | -3.382 |
| EBIT / assets | -1.074 |
| Equity / liabilities | 0.829 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
| KYNB | KYNTRA BIO, INC. | 3/9 | — | 0.2 | -78.3% |
| IMNM | Immunome Inc. | 3/9 | 13.87 | — | — |
| ABEO | ABEONA THERAPEUTICS INC. | 4/9 | -5.75 | 4.5 | — |
| WHWK | Whitehawk Therapeutics, Inc. | 2/9 | 2.98 | — | -72.5% |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
FAQ
Is KRRO financially healthy?
Korro Bio, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does KRRO pay a dividend?
No, Korro Bio, Inc. does not currently pay a dividend.
How profitable is KRRO?
In FY2025, Korro Bio, Inc. had a net margin of -1834.5% and a return on equity of -228.0%.
What is the analyst price target for KRRO?
The average Wall-Street price target for Korro Bio, Inc. is $20.00, about 49.8% above the recent price, from 10 analysts (consensus: strong buy).
Is KRRO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Korro Bio, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.